Status:
COMPLETED
Special Drug-Use Surveillance Study on Vedolizumab for IV Infusion 300 mg [Ulcerative Colitis]
Lead Sponsor:
Takeda
Conditions:
Ulcerative Colitis
Eligibility:
All Genders
Brief Summary
The purpose of this survey is to evaluate the long-term safety and effectiveness of vedolizumab for intravenous (IV) infusion 300 milligrams (mg) in ulcerative colitis (UC) patients in the routine cli...
Detailed Description
The drug being tested in this study is called vedolizumab for IV infusion 300 mg. This drug is being tested to treat patients who have UC. This study is an observational (non-interventional) study an...
Eligibility Criteria
Inclusion
- Have moderate or severe active UC
- Have inadequate response to existing therapies
Exclusion
- Patients with any contraindication for vedolizumab
Key Trial Info
Start Date :
February 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 12 2025
Estimated Enrollment :
1110 Patients enrolled
Trial Details
Trial ID
NCT03824561
Start Date
February 1 2019
End Date
February 12 2025
Last Update
September 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Takeda Selected Site
Tokyo, Japan